{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:55:00Z","timestamp":1790805300293,"version":"4.1.0"},"reference-count":39,"publisher":"Open Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and many options available may not be feasible. This review presents the background, clinical studies, and indications for the use of Risdiplam in treating SMA. SMA causes a decrease in the production of survival motor neuron proteins (SMN) and current treatments target to increase the expression of SMN. Risdiplam is the first and only oral medication to be approved to treat SMA. As an SMN2 splicing modifier, it has provided stronger systemic therapies than previous intrathecal and gene replacement therapies. There have been many efforts to treat SMA with multidisciplinary approaches. These include intrathecal injections to gene replacement therapies. However, these have been faced with limitations such as reaching a good therapeutic dose in systemic tissues, route of administration, and price. Risdiplam is currently the only orally administered drug approved by the FDA for the treatment of SMA. It not only provides a good therapeutic window to systemic tissues but allows for a non-invasive approach in infants. Further investigation and comparison on the safety profile of Risdiplam due to its broader systemic effect should be considered with other available therapies.<\/jats:p>","DOI":"10.52965\/001c.25579","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T03:18:58Z","timestamp":1627874338000},"source":"Crossref","is-referenced-by-count":29,"title":["Risdiplam for the Use of Spinal Muscular Atrophy"],"prefix":"10.52965","volume":"13","author":[{"given":"Juyeon","family":"Kakazu","sequence":"first","affiliation":[{"name":"Georgetown University School of Medicine, Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakoma L.","family":"Walker","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Sciences Center, Shreveport, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Claire","family":"Babin","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Sciences Center, Shreveport, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Trettin","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Sciences Center, Shreveport, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lee","sequence":"additional","affiliation":[{"name":"Creighton University School of Medicine-Phoenix Regional Campus, Phoenix, AZ","department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia B.","family":"Sutker","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Sciences Center New Orleans, LA","department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA","department":["Department of Pharmacy Practice"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Sciences Center, Department of Anesthesiology, New Orleans, LA; Provost, Chief Academic Officer, Vice-Chancellor of Academic Affairs, Professor, Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, LSU Health Shreveport"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"30777","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"W. David Arnold","year":"2015","journal-title":"Muscle and Nerve","ISSN":"https:\/\/id.crossref.org\/issn\/1097-4598","issn-type":"print"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/brain\/93.1.15","article-title":"Electromyography and muscle biopsy in infantile spinal muscular atrophy","volume":"93","author":"Fritz Buchthal","year":"1970","journal-title":"Brain","ISSN":"https:\/\/id.crossref.org\/issn\/0006-8950","issn-type":"print"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0022-510X(76)90082-4","article-title":"International collaborative study of the spinal muscular atrophies. Part 1. Analysis of clinical and laboratory data","volume":"29","author":"Alan E.H. Emery","year":"1976","journal-title":"Journal of the Neurological Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/0022-510X","issn-type":"print"},{"issue":"3","key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.08.016","article-title":"Prevalence and risk factors for feeding and swallowing difficulties in spinal muscular atrophy types II and III","volume":"160","author":"Yen Shan Chen","year":"2012","journal-title":"Journal of Pediatrics","ISSN":"https:\/\/id.crossref.org\/issn\/1097-6833","issn-type":"print"},{"issue":"8","key":"ref5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1177\/0883073807305670","article-title":"Modern management of spinal muscular atrophy","volume":"22","author":"Susan T. Iannaccone","year":"2007","journal-title":"Journal of Child Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0883-0738","issn-type":"print"},{"issue":"2","key":"ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Eugenio Mercuri","year":"2018","journal-title":"Neuromuscular Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/1873-2364","issn-type":"print"},{"issue":"2","key":"ref7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"5","author":"Jacqueline Glascock","year":"2018","journal-title":"Journal of neuromuscular diseases","ISSN":"https:\/\/id.crossref.org\/issn\/2214-3599","issn-type":"print"},{"issue":"6","key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Agn\u00e8s Poirier","year":"2018","journal-title":"Pharmacology Research and Perspectives","ISSN":"https:\/\/id.crossref.org\/issn\/2052-1707","issn-type":"print"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives.","volume":"15","author":"Tamara Dangouloff","year":"2019","journal-title":"Therapeutics and clinical risk management","ISSN":"https:\/\/id.crossref.org\/issn\/1176-6336","issn-type":"print"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291LK","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives","volume":"15","author":"D. T.","year":"2019","journal-title":"Therapeutics and Clinical Risk Management","ISSN":"https:\/\/id.crossref.org\/issn\/1178-203X","issn-type":"print"},{"issue":"7","key":"ref11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sj.ejhg.5201821","article-title":"Population screening and cascade testing for carriers of SMA","volume":"15","author":"Melanie Smith","year":"2007","journal-title":"European Journal of Human Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/1018-4813","issn-type":"print"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1","author":"Omar Dabbous","year":"2019","journal-title":"Advances in Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/1865-8652","issn-type":"print"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Daniel C. Malone","year":"2019","journal-title":"Journal of Market Access & Health Policy","ISSN":"https:\/\/id.crossref.org\/issn\/2001-6689","issn-type":"print"},{"issue":"7","key":"ref14","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/jcm9072222","article-title":"New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges","volume":"9","author":"Sonia Messina","year":"2020","journal-title":"Journal of Clinical Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/2077-0383","issn-type":"print"},{"key":"ref15","first-page":"7916","article-title":"SMN protein levels before and after treatment with risdiplam ( RG7916 ) in patients with Type 1 to 3 SMA compared to healthy subjects","author":"Heidemarie Kletzl","year":"2018"},{"issue":"1","key":"ref16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier","volume":"85","author":"Stefan Sturm","year":"2019","journal-title":"British Journal of Clinical Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1365-2125","issn-type":"print"},{"issue":"8","key":"ref17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Daniel D. Coovert","year":"1997","journal-title":"Human Molecular Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/0964-6906","issn-type":"print"},{"issue":"8","key":"ref18","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1172\/JCI58752","article-title":"Of SMN in mice and men: A therapeutic opportunity","volume":"121","author":"Kathryn J. Swoboda","year":"2011","journal-title":"Journal of Clinical Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"issue":"15 Supplement","key":"ref19","article-title":"FIREFISH Part 1: 1-Year Results on Motor Function in Babies with Type 1 SMA (S25.003)","volume":"92","author":"Giovanni Baranello","year":"2019","journal-title":"Neurology"},{"issue":"15 Supplement","key":"ref20","article-title":"FIREFISH Part 1: Survival, Ventilation and Swallowing Ability in Infants with Type 1 SMA Receiving Risdiplam (RG7916) (S25.008)","volume":"92","author":"Laurent Servais","year":"2019","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1016\/j.nmd.2019.06.515","article-title":"P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy","volume":"29","author":"G. Baranello","year":"2019","journal-title":"Neuromuscular Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0960-8966","issn-type":"print"},{"key":"ref22","series-title":"eLS","article-title":"Spinal Muscular Atrophy","author":"Michelle A Farrar","year":"2011"},{"issue":"15 Supplement","key":"ref23","article-title":"FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA) (1302)","volume":"94","author":"Laurent Servais","year":"2020","journal-title":"Neurology"},{"issue":"5-6","key":"ref24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA Consortium Meeting (26-28 June 1992, Bonn, Germany)","volume":"2","author":"Theodore L. Munsat","year":"1992","journal-title":"Neuromuscular Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0960-8966","issn-type":"print"},{"issue":"April","key":"ref25","article-title":"Roche IR - AAN 2020 Highlights","author":"Roche Analyst","year":"2020"},{"issue":"9","key":"ref26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Richard S. Finkel","year":"2014","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1526-632X","issn-type":"print"},{"issue":"July","key":"ref27","first-page":"6","article-title":"Type 2 or 3 SMA Supplementary page ( This page provides additional online content and will not be available at the","volume":"02908685","author":"E Mercuri","year":"2018"},{"issue":"15 Supplement","key":"ref28","article-title":"Update from SUNFISH Part 1: Safety, Tolerability and PK\/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)","volume":"92","author":"Eugenio Mercuri","year":"2019","journal-title":"Neurology"},{"issue":"15 Supplement","key":"ref29","article-title":"SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260)","volume":"94","author":"Eugenio Mercuri","year":"2020","journal-title":"Neurology"},{"issue":"15 Supplement","key":"ref30","article-title":"JEWELFISH: Safety and Pharmacodynamic Data in Non-Na\u00efve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam (RG7916) (772)","volume":"94","author":"Claudia Chiriboga","year":"2020","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1016\/j.nmd.2019.06.524","article-title":"P.362RAINBOWFISH: A study of risdiplam (RG7916) in newborns with pre-symptomatic spinal muscular atrophy (SMA)","volume":"29","author":"E Bertini","year":"2019","journal-title":"Neuromuscular Disorders","ISSN":"https:\/\/id.crossref.org\/issn\/0960-8966","issn-type":"print"},{"issue":"5","key":"ref32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/archneurpsyc.1956.02330230050005","article-title":"Heredofamilial juvenile muscular atrophy simulating muscular dystrophy.","volume":"75","author":"E Kugelberg","year":"1956","journal-title":"A.M.A. archives of neurology and psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0096-6886","issn-type":"print"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy","volume":"162","author":"Michelle A Farrar","year":"2013","journal-title":"The Journal of Pediatrics","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3476","issn-type":"print"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0884217503261125","article-title":"Spinal muscular atrophy in the neonate","volume":"33","author":"Jennifer A. Markowitz","year":"2004","journal-title":"JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing","ISSN":"https:\/\/id.crossref.org\/issn\/0884-2175","issn-type":"print"},{"issue":"8","key":"ref35","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: Clinical classification and disease heterogeneity","volume":"22","author":"Barry S. Russman","year":"2007","journal-title":"Journal of Child Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0883-0738","issn-type":"print"},{"issue":"10","key":"ref36","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/hmg\/7.10.1531","article-title":"The role of the SMN gene in proximal spinal muscular atrophy","volume":"7","author":"Suzie Lefebvre","year":"1998","journal-title":"Human Molecular Genetics","ISSN":"https:\/\/id.crossref.org\/issn\/0964-6906","issn-type":"print"},{"issue":"3","key":"ref37","doi-asserted-by":"publisher","first-page":"e0213680","DOI":"10.1371\/journal.pone.0213680","article-title":"Systemic nature of spinal muscular atrophy revealed by studying insurance claims","volume":"14","author":"Scott L. Lipnick","year":"2019","journal-title":"PLoS ONE","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"issue":"3","key":"ref38","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI131989","article-title":"Muscle-specific SMN reduction reveals motor neuron\u2013independent disease in spinal muscular atrophy models","volume":"130","author":"Jeong Ki Kim","year":"2020","journal-title":"Journal of Clinical Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/1558-8238","issn-type":"print"},{"key":"ref39","first-page":"2018","article-title":"JEWELFISH : Risdiplam ( RG7916 ) increases SMN protein in non-na\u00efve patients with SMA JEWELFISH : Risdiplam ( RG7916 ) increases SMN protein in non-na\u00efve patients with SMA Supplementary page ( This page provides additional online content and will not be i","volume":"03032172","author":"C A Chiriboga","year":"2018","journal-title":"I23rd nternational Annual Congress of the World Muscle Society, Mendoza, Argentina"}],"container-title":["Orthopedic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/25579-risdiplam-for-the-use-of-spinal-muscular-atrophy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T20:10:29Z","timestamp":1739304629000},"score":1,"resource":{"primary":{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/25579-risdiplam-for-the-use-of-spinal-muscular-atrophy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.25579","relation":{},"ISSN":["2035-8164"],"issn-type":[{"value":"2035-8164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]}}}